24/7 Market News Snapshot 22 August, 2024 – ENDRA Life Sciences Inc. Common Stock (NASDAQ:NDRA)

August 22, 2024

DENVER, Colo., 22 August, 2024 (247marketnews.com) – (NASDAQ:NDRA) are discussed in this article.
ENDRA Life Sciences Inc. (NDRA) has recently garnered significant attention from investors, with shares opening at $0.43 and experiencing a notable increase of approximately 8.61%, reaching a current price of $0.477. This surge is accompanied by a substantial trading volume of 16.24 million shares, underscoring a heightened investor interest and potential momentum. Observing key support levels around $0.43 and resistance near $0.50 will be crucial for traders as this bullish trend may indicate either a reversal or continuation of positive momentum.

In parallel, ENDRA has released its financial results for the second quarter of 2024, showcasing commendable advancements in operational efficiencies and strategic growth initiatives. Following recent leadership transitions, Alexander Tokman has taken on the role of acting CEO, leveraging over 24 years of commercial leadership experience. He is joined by other industry veterans, including Richard Jacroux as CFO and Ziad Rouag as Head of Regulatory and Clinical Affairs, collectively enhancing the executive team with their financial and clinical expertise.

During this quarter, ENDRA has made significant strides in its regulatory initiatives in the U.S. After a crucial meeting with the U.S. Food and Drug Administration (FDA), the company aligned on its clinical and statistical plans for the Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, an essential step towards achieving regulatory approval. Pilot clinical trials are underway in North America, with plans to expand into Europe, which will leverage data for future regulatory submissions.

To ensure financial stability, ENDRA raised $8.0 million through a public offering while successfully reducing annual operating expenses by $3.1 million. This strategic financial management empowers the company to concentrate on its clinical and regulatory objectives. With an impressive portfolio of 81 issued patents worldwide, ENDRA continues to explore new clinical applications for TAEUS, positioning itself as a leader in transformative, non-invasive diagnostics in the healthcare market.

Related news for (NDRA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.